Anika Therapeutics Inc. (ANIK) Insider Trading

Last 12 months

Insiders bought $264k on the open market and sold nothing.

Net open-market

+$264k

3 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

3 / 0

executives and directors

Last open-market buy

Aug 2026

Aug 4, 2026

Get an email when ANIK's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 3 – 4	Gary P Fischetti Director	Bought 2 parts	2,000	$20.54 average	$41k	3.8%	Form 4
May 1	John B Henneman III Director	Bought	5,000	$14.66	$73k	10%	Form 4
Apr 30	Stephen D. Griffin President and CEO	Bought	12,200	$12.29	$150k	51%	Form 4

Aug 3 – 4
Gary P Fischetti
Director · bought 2,000 at avg $20.54
$41k
3.8% of stake
May 1
John B Henneman III
Director · bought 5,000 at $14.66
$73k
10% of stake
Apr 30
Stephen D. Griffin
President and CEO · bought 12,200 at $12.29
$150k
51% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ANIK, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Surgical & Medical Instruments & Apparatus

XTNTXtant Medical Holdings Inc.

BBNXBeta Bionics Inc.

OSUROrasure Technologies Inc.

NPCENeuroPace Inc.

INFUInfuSystem Holdings Inc.

MHUAFMeihua International Medical Technologies Co., Ltd.

KMTSKestra Medical Technologies, Ltd.

DCTHDelcath Systems Inc.

Spot a number that looks wrong? Check it in ANIK's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ANIK

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.